About Us
Dr. Goodenowe™ is dedicated to advancing healthcare through innovative research and practical applications. We are committed to improving how scientific knowledge is translated into real-world health practices.
We support individuals with education, community, and practical tools that encourage informed engagement in their own well-being. We also support healthcare practitioners with training, technology, and resources designed to enhance their ability to integrate emerging science into their professional practices.
For decades, scientific research has produced a substantial body of knowledge about the biological foundations of health and how various factors can influence functional outcomes over time. Despite these advances, integrating complex scientific insights into everyday practice remains a significant challenge.
This is where Dr. Goodenowe™ focuses its efforts. Our mission is to help bridge the gap between scientific research and practical application by providing approaches, tools, and educational resources that make emerging scientific knowledge more accessible and actionable within real-world health contexts.
Dr. Dayan Goodenowe
Dr. Dayan Goodenowe, PhD, is a neuroscientist, biochemist, inventor, and clinical research expert. In 1999, he invented and patented ion cyclotron resonance mass spectrometry technology, enabling comprehensive monitoring of human biochemistry for the first time.
Using this technology, Dr. Goodenowe analyzed blood samples from tens of thousands of individuals of all ages and races, from multiple countries. The biochemistry of healthy individuals was compared with that of individuals experiencing a wide range of diseases. Over 20 conditions were studied, including autism, dementia, colon cancer, heart disease, and others. Differences between the biochemistry of younger and older populations, as well as associations with all-cause mortality, were also examined.
This body of research identified early biochemical patterns associated with disease and mortality risk, thereby contributing to the development of an extensive patent portfolio. These patents cover diagnostic tests for early detection and screening across numerous conditions, including specific cancers, neurological disorders, psychiatric conditions, and cardiovascular disease.
Dr. Goodenowe is also the author of Breaking Alzheimer’s, which documents his research journey and examines the biochemical findings that informed his work in neurodegeneration and lipid biology.
What do we do?
At Dr. Goodenowe™, we utilize cutting-edge scientific research and innovative products developed by Dr. Dayan Goodenowe to empower individuals and healthcare practitioners. Our mission is to advance health through science-based education and solutions that help individuals improve their well-being.
In 2016, Dr. Dayan Goodenowe began translating his 25 years of research into a new organizational model for health research and education. By 2024, he had built an integrated infrastructure to support future research, development, and implementation efforts.
The Restorative and Perpetual Health Model
Dr. Goodenowe™ is dedicated to advancing a next-generation approach to health that emphasizes long-term function and resilience throughout the lifespan.
Over the past century, healthcare systems have focused primarily on urgent medical needs such as acute illness, injury, and infectious disease. These efforts have led to significant improvements in population health and life expectancy, and remain essential to the protection of public health.
The needs of today’s population increasingly relate to long-term health management, quality of life, and age-related functional decline. Addressing these needs involves a broader focus on supporting and maintaining health at every stage of life—from early development through older adulthood.
Meeting these needs requires new models of care and infrastructure that complement the existing healthcare system. These approaches can coexist with and strengthen traditional medical services by emphasizing proactive, supportive, and educational strategies that promote overall well-being.
It is an ambitious vision, but one that is already underway.
- ✓ Laboratory Infrastructure
- ✓ Imaging Infrastructure – 3T MRI
- ✓ Manufacturing Infrastructure
- ✓ Protocols
- ✓ Advanced practitioner network
- ✓ Restorative Health Center
- ✓ Rare diseases
- ✓ Community training
- ✓ Outcome measurements
- ✓ Large-scale community roll-out financed by healthcare savings
- ✓ Products and services offered to communities at no cost
Dr. Goodenowe’s Restorative and Perpetual Health model is about focusing on and reinforcing the physical and emotional elements that make us human. Health is inclusive. Health is unifying. Health also needs a purpose to be sustainable. That is where the community cannot be overlooked. Our families, our friends, our co-workers, and our communities, small and large, all contribute to our ability to sustain our health.
Our History
A Scientific Timeline
Dr. Goodenowe’s journey in biochemical research and innovation spans over four decades, marked by groundbreaking discoveries and significant contributions to medical science.
This timeline highlights key milestones in his career and the formation and growth of Dr. Goodenowe™. Each step reflects Dr. Goodenowe’s dedication to advancing science and improving human health.
1989-90 – Completed research thesis on structure activity of hallucinogenic activity of designer amphetamines
1990 – Completed BSc
1990-1993 – Performed extensive research on the serotonergic, noradrenergic and biogenic amine pathways in the brain and their role in mood disorders
1993 – Completed PhD thesis on mechanisms of action of drugs used to treat refractory depression
1993-1995 – Researched the structure and activity of GABA receptors and how neuroactive steroids allosterically modulate GABA functions in the brain. Was the first to discover the three-dimensional orientation changes in neuroactive steroids responsible for activity using supercomputer technology, such that medicinal chemistry modifications could be made on novel structural neurosteroid design.
1993-1995 – Researched the structure and activity of NMDA receptors and how glycine and D-serine allosterically modulate NMDA functions in the brain. Invented a novel derivatization reagent and analytical method that enabled D-serine to be separated from L-serine using standard GC-MS technology. Elucidated the biochemical relationships between D- and L-phosphoserine and D- and L-serine.
1995-1999 – Developed advanced GC-MS, LC-MS, and LC-MS/MS technologies and methods for detecting and quantifying trace levels of environmental contaminants in soil and groundwater. Set up laboratories worldwide and trained laboratory personnel on advanced trace-level mass spectrometry techniques.
1999 – Invented and patented comprehensive non-targeted metabolomic technology using Fourier Transform Ion Cyclotron Resonance Mass Spectrometry
2000-2016 - Founded and managed (as CEO, chairman, and majority shareholder) Phenomenome Discoveries Inc., an advanced biotechnology company, to further research and develop non-targeted metabolomic technology and its application to functional genomics, diagnostics, and therapeutic drug development. Phenomenome Discoveries was valued at over 500M USD prior to its dissolution in 2016.
2000-2006 – Performed extensive functional genomics research in multiple species of cells, plants, and animals. Evaluated the biochemical and phenotypic effects of gene insertions, deletions, environmental toxins, nutrients, and drugs on biological systems.
2002 – Invented and patented a novel bioinformatic method of processing and visualizing non-targeted metabolomic data
2002 – Published the world’s first non-targeted systems biology paper. Comprehensive gene expression data was combined with comprehensive metabolomic data for the first time to monitor developmental changes in strawberries during fruit ripening and its use in mechanistic elucidation of gene function in transgenic tobacco plants with different colored flowers.
2004 – Published one of the most cited plant biochemistry papers on the integration of transcriptomics and metabolomics
2004 – Published how to use advanced FTICR-MS to identify active ingredients in medicinal herbs
2005 – Invented and patented a novel FTICR-MS instrument design for non-targeted metabolomics
2005 – Discovered novel serum metabolomic biomarkers of colon cancer and patented diagnostic test for colon cancer
2005 - Discovered novel serum metabolomic biomarkers of ovarian cancer and patented diagnostic test for ovarian cancer
2006 – Published biochemical network prediction technology using FT-ICR Mass spectrometry and advanced bioinformatics
2006 - Discovered novel serum metabolomic biomarkers of multiple sclerosis and patented diagnostic test for multiple sclerosis
2006 – Invented core plasmalogen restoration technology (plasmalogen precursors) and patented their use for the treatment of dementia. PPI-1005 is the progenitor of ProdromeNeuro™
2006 - Discovered novel serum metabolomic biomarkers of dementia and other neurological disorders and patented diagnostic test for dementia
2007 - Discovered novel serum metabolomic biomarkers of autism and patented diagnostic test for autism
2007 – Discovered and patented plasmalogen deficiency-mediated diseases of aging
2007 – Published definitive clinical research results on the causative role of plasmalogen deficiency on cognitive impairment and Alzheimer’s
2008 – Invented and patented non-natural pharmaceutical derivatives of PPI-1005 amenable to composition of matter patents. Lead candidates were PPI-1011, PPI-1017, and PPI-1025.
2009 – Published results of the longitudinal trial in autism describing the definitive role of mitochondrial insufficiency as a key causal factor
2010 – Published definitive research on prodromal biomarkers of colon cancer and mechanisms of colon cancer risk
2010 – Published structure-activity relationship of plasmalogen precursors on membrane composition and cholesterol regulation
2011 - Published structure-activity relationship of plasmalogen precursors on membrane composition and amyloid production
2011 – Published oral bioavailability, metabolism and distribution of PPI-1011 (a DHA plasmalogen precursor) in rabbits.
2011 – Published definitive book chapter on the biochemical basis of autism
2011 – Invented and patented injectable plasmalogen precursors. The lead candidate was PPI-1040.
2013 – Published biomarkers of pancreatic cancer with diagnostic accuracy >95%
2013 – Published research results from a colonoscopy trial showing 86% sensitivity for detecting early-stage colon cancer with a simple blood test
2015 – Published post-market evaluation on 14,995 colon cancer screening blood tests showing performance far exceeding current standard of care
2015 – Published research results showing that plasmalogen precursors prevented neurodegeneration in an animal model of Parkinson's
2015 – Published comparative study of metabolic biomarkers of pancreatic cancer versus CA19-9 showing superior performance of the metabolic biomarkers
2015 – Published research results on biomarkers of multiple sclerosis and their relationship to severity and disease duration
2015 – Published research results showing that changes in phosphatidylcholine levels in Alzheimer's disease and dementia are caused by impaired peroxisomal function
2016 – Published validation studies confirming diagnostic accuracy of biochemical biomarkers in pancreatic cancer
2016 – Presented definitive diagnostic research involving multiple sites from multiple countries on prodromal biomarkers of ovarian cancer with diagnostic accuracy > 95%
2016 – Published research results showing that plasmalogen precursors reverse neurodegeneration in animal model of Parkinson's
2016 - Founded Prodrome Science to expand and extend previous pharmaceutical and diagnostic research at Phenomenome Discoveries into restorative biochemical health interventions and health monitoring technologies amenable to large-scale community health programming
2018 – Developed novel DHA purification technology for the production of purified DHA from natural sources such as fish or algae oil
2018 – Invented novel synthetic procedure to manufacture natural 1-O-alkyl, 2,3-diacyl glycerol plasmalogen precursors. ProdromeGlia™ and ProdromeNeuro™ are the final products of this procedure.
2019 – Published epidemiological evidence that APOE e4 carriers with high blood plasmalogen levels do not have an increased risk of dementia
2019 – Released dietary supplement version of omega-3 DHA plasmalogen precursor (ProdromeNeuro)
2020 - Released dietary supplement version of omega-9 oleic acid plasmalogen precursor (ProdromeGlia)
2020 – Released ProdromeScan™ – a compilation of key biomarker discoveries for monitoring human health
2020 – Published confirmatory clinical data using ADNI dementia cohort on the relationship between plasmalogen deficiency and dementia
2020 – Published research results showing decreased plasmalogens in bipolar disorder
2021 – Published Breaking Alzheimer’s – a 15-Year Crusade to Expose the Cause and Deliver the Cure
2022 – Published first clinical trial of plasmalogen precursor treatment in persons suffering from cognitive impairment – ProdromeNeuro improved cognition and mobility
2022 – Published definitive human brain post-mortem data on the relationship between brain plasmalogen levels and cognition
2022 – started Rare Disease Charity with a focus on RCDP
2023 – opened Restorative Health Center
2024 – opened Community Health Center
Explore Dr. Goodenowe's research and innovation:
Frequently asked questions
In an era of overwhelming and often incorrect information, Dr. Goodenowe's research and education are noted for their practicality. He focuses not just on symptom management but also on identifying and treating prodromes to restore biochemical and system health.
Dr. Goodenowe is not a medical doctor but works closely with medical doctors who implement his products and protocols. Over 4000 health professionals are currently in the Dr. Goodenowe Practitioner program.
We conduct observational trials to understand health deviations, intervention trials to test biochemical solutions, and adaptive trials to refine treatments based on participant responses. Our studies cover aging, cancer, neurological diseases, and more, aiming to improve health outcomes. Learn about our ongoing and completed trials and their impact.
For detailed information, visit our clinical trials page.
Visit the Dr. Goodenowe Perpetual Health website for more information on our programs focused on a restorative health approach to specific conditions.
Use our Practitioner Directory to find qualified practitioners who are familiar with Dr. Goodenowe's research and protocols.
We have a support group to help parents who have a child with a known peroxisomal or plasmalogen deficiency disease or who have a child with symptoms of autism, PANDAS, or delayed neurological development. This is a safe and welcoming space for those seeking information that may be useful to them in the care of their child.
Pediatric Plasmalogen Deficiencies and Related Disorders Recovery Group
Visit Dr. Goodenowe Community Health to learn more about our initiatives and community programs.